Webinar: How a Novel Molecular Screening Technology for Blood-Related Cancers Can Provide Operational and Cost-Effective Benefits to Your Lab
FOR IMMEDIATE RELEASE
THE DARK REPORT
21806 Briarcliff Dr.
Spicewood, TX 78669
Media Contact: Kristen Noonan
AUSTIN, Texas (June 3, 2021) – DARK Daily today announced the June 9, 2021 free webinar for molecular labs and pathology groups, “How a Novel Molecular Screening Technology for Blood-Related Cancers Can Provide Operational and Cost-Effective Benefits to Your Lab.” This webinar presents the benefits of Precipio‘s HemeScreen, a novel, proprietary technology that offers an alternative to the existing molecular testing modalities for blood-related cancers.
Current molecular testing modalities for blood-related cancers are cumbersome to operate and subsequently generate poor economics—forcing laboratories to batch large samples, resulting in slow turnaround time, or avoid the process entirely and send these tests out. HemeScreen presents an opportunity for laboratories to bring tests in-house that have otherwise not been economically viable.
During this free webinar, Precipio’s leadership team—Medical Director Frank Bauer, MD, CTO Ayman Mohamed, MD, and CEO Ilan Danieli—will discuss the clinical, operational, and economic impact of implementing HemeScreen. They’ll present a case study to share how a five-physician practice on the East Coast implemented HemeScreen in its office laboratory and continues to evolve with the technology. You will hear why the practice adopted HemeScreen, the setup and workflow involved, the outcomes the practice has experienced so far, and the plans for expansion.
Attend this 60-minute program, and you will:
- Understand the differences between current technologies used and HemeScreen—and their advantages and disadvantages relative to HemeScreen
- Hear about HemeScreen’s operational impact on the lab in terms of workflow, TAT, and economics
- Learn about HemeScreen’s ease of adoption and implementation into lab workflow
- Understand the clinical effects of HemeScreen to the customer (the treating oncologist)
- Have the opportunity to pose specific questions and connect directly with the panel during a Q&A session
HemeScreen can empower laboratories to deliver substantial clinical benefits to their oncology customers, enable them to follow updated clinical guidelines, and expand their test offering while reducing turnaround time. Together, these benefits ultimately provide higher quality diagnostic information to oncologists and their patients.
“How a Novel Molecular Screening Technology for Blood-Related Cancers Can Provide Operational and Cost-Effective Benefits to Your Lab” is available for free, live access Wednesday, June 9, 2021 at 1 PM EST and on-demand thereafter.
Click here to register and get more info on this webinar.
For additional info, contact: Amanda Curtis, 512-264-7103
About DARK Daily: DARK Daily is a concise e-news/management briefing on timely topics in clinical laboratory and anatomic pathology group management. It is a solution to the dilemma facing anyone in the laboratory profession. New developments, new technology, and changing healthcare trends make it imperative to stay informed to be successful. At the same time, the Internet, cell phones, tablets, laptop computers, and wireless devices are overwhelming any one individual’s ability to absorb this crushing Tsunami of data.